Study of Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery. (MUSCAADE)

April 1, 2019 updated by: University Hospital, Toulouse

Pilot Study of Branched Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.

Despite the demonstrable health and quality of life benefits, there are unknowns within consequences of obesity surgery. Weight loss composition is poorly understood. The objective is to have a significant loss of body fat and a limited loss of muscular weight.

A cohort study in the nutrition unit at Toulouse University Hospital shows that 3 months and 1 year after surgery, there are 2 phenotypes of patients. The first one is called 'little loss' and is defined by a contribution of muscular weight lower than 15% of the total weight loss. The other one is called 'big loss' and is defined by a contribution of muscular weight higher than 15% of the total weight loss. Causes of these different phenotypes are unknown for the moment.

Some amino acids have an anabolic potential. Leucine induces a muscular protein synthesis in clinical situations like hepatic cirrhosis, and some populations like new born and older people.

Assuming that, a leucine-enriched essential amino acid supplementation will have a benefit effect on the muscular mass. That is testing the influence of the quality of protein consumed, more than the quantity. An anabolic substance (amino acid here) can lead to gain of muscle only if it is associated to regular physical training, all patients will follow a physical training.

Study Overview

Detailed Description

An excessive loss of lean mass could have negative metabolic consequences. Indeed, lean mass is an essential determinant of weight loss and of the glycaemia regulation. An important loss of muscular mass could expose the person to a reduction of quality of life (because of fatigue), or even a functional loss. Muscles are important for insulin sensibility and glucose metabolism. Muscles are proteolysis target and proteins will be used as sources of amino acid for other cellular functions.

Changes in lean mass have been at the centre of several studies, but changes in muscular mass after bariatric surgery have been report only one time.

A cohort study in the nutrition unit at Toulouse University Hospital shows that 3 months and 1 year after surgery, there are 2 phenotypes of patients. The first one is called 'little loss' and is defined by a contribution of muscular weight lower than 15% of the total weight loss. The other one is called 'big loss' and is defined by a contribution of muscular weight higher than 15% of the total weight loss. Causes of these different phenotypes are unknown for the moment. Nothing distinguishes them before the surgery. Type of surgery, gender, protein intake (in grams of proteins intake per day) do not appear to have a determining influence about the intensity of muscle mass loss. The only other study published shows changes in muscular mass about 15% at 6 weeks.

Relation between glycaemia changes and muscle mass changes suggests that patients with modest changes in muscular mass are patients who have the best improvement of glycaemia after surgery. It is the reason why, it could be interesting to preserve muscular mass.

Nowadays, there is no consensual strategy to compensate this loss of muscle mass. It is important to have in the same time an anabolic stimulus (training, hormone…) and a sufficient energy and protein intake.

According to a recent study which compares leucine intake with placebo during weight loss driven by a low-calorie diet associated to a muscle strengthening exercises, patients loss the same weight, but leucin group is gaining lean mass, while placebo group is losing it. Accordingly, twe different doses of amino acid will be tested of those used as diet supplement.

This study is testing the influence of the quality of protein consumed, more than the quantity. Patients will take leucine-enriched amino acid supplement and follow physical training. Aromatic amino acid supplementation showed an anabolic effect in older people, undernourished children and undernourished patients with chronic obstructive pulmonary disease. There are no known side effects. This amino acid supplementation has not been evaluated in post-obesity surgery context.

Study Type

Interventional

Enrollment (Actual)

6

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Toulouse, France, 31059
        • Department of Endocrinology, metabolic diseases and nutrition

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient older than 18 years of age and younger than 65 years of age,
  • Patient received an obesity-surgery (gastric bypass or sleeve gastrectomy)
  • Contribution of muscular weight higher than 15% of the total weight loss after the third month post-surgery.
  • Patient that be able to increase their physical activity
  • Patient that give their informed consent before any procedure for the study
  • Patient affiliated with a health insurance scheme

Exclusion Criteria:

  • Patients allergic to one of the supplement's compound.
  • Patients with glucocorticoid therapy
  • Patients with hyperthyroidism
  • Patients commencing insulin treatment or growth hormone
  • Protein powder intake (as nutritional complement or as anabolic substance for muscle building practice)
  • Oral nutritional supplement intake for malnutrition
  • Bone fracture since the surgery
  • Infection can cause hypercatabolism (like microbial outbreak or chronic gastric fistula)
  • Hospitalization for more than 24 hours since the surgery
  • Known physical handicap
  • Inability to increase physical activity during 3 months after beginning of the supplementation
  • Enteral or parenteral nutrition
  • Patients over 158 kg (DEXA impossible)
  • Protected adults (guardianship by court order)
  • Pregnant woman or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Leucine-enriched amino acid : 2.16g/day
Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
Experimental: Leucine-enriched amino acid : 4g/day
Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in appendicular muscular mass at 3 months
Time Frame: Baseline and 3 months
Appendicular muscular mass measured by dual-energy X-ray absorptiometry (DEXA). It will be measured before and 3 months after supplementation.
Baseline and 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in limbs muscular force at 3 months
Time Frame: Baseline and 3 months
The lower and higher limbs muscular force will be measured with a strain gauge.
Baseline and 3 months
Change from baseline in muscular function at 3 months
Time Frame: Baseline and 3 months
400 meters walking speed
Baseline and 3 months
Change from baseline in muscular function at 3 months
Time Frame: Baseline and 3 months
Chair-stand test
Baseline and 3 months
Change from baseline in muscular function at 3 months
Time Frame: Baseline and 3 months
Balance test by the Short Physical Performance Battery test
Baseline and 3 months
Change from baseline in fatigue at 3 months
Time Frame: Baseline and 3 months
Fatigue will be evaluate by the Pichot scale
Baseline and 3 months
Change from baseline in general functional assessment at 3 months
Time Frame: Baseline and 3 months
General function will be assessed by the Functional Status Questionnaire test.
Baseline and 3 months
Change from baseline in protein daily intake at 3 months
Time Frame: Baseline and 3 months
Patient will evaluate his/her protein daily intake (in g/day) by the Protein Intake Monitor with a digital tablet
Baseline and 3 months
Change from baseline in physical training adhesion at 3 months
Time Frame: Baseline and 3 months
Patients will have an exercise diary to write their organised physical activity. Physical activity will be converted in a multiple of basal metabolic rate.
Baseline and 3 months
Change from baseline in glucose metabolism at 3 months
Time Frame: Baseline and 3 months
Oral glucose tolerance test will be performed and glucose concentration will be determined into the blood.
Baseline and 3 months
Change from baseline in insulin secretion at 3 months
Time Frame: Baseline and 3 months
Oral glucose tolerance test will be performed and insulin concentration will be determined into the blood.
Baseline and 3 months
Change from baseline in leucine compliance
Time Frame: Baseline and 3 months
Leucine concentration and variation between visit before and after 3 months of supplementation will be measured by chromatography to assess the patient's compliance
Baseline and 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: RITZ Patrick, MD PhD, University Hospital, Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2017

Primary Completion (Actual)

July 13, 2017

Study Completion (Actual)

July 13, 2017

Study Registration Dates

First Submitted

March 9, 2016

First Submitted That Met QC Criteria

March 17, 2016

First Posted (Estimate)

March 23, 2016

Study Record Updates

Last Update Posted (Actual)

April 3, 2019

Last Update Submitted That Met QC Criteria

April 1, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • RC31/15/7649
  • 2015-A01226-43 (Other Identifier: RCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week

3
Subscribe